GLP-1 Drugs Reshape Obesity Care, Cutting Cardiac Events 20% as New Oral Options Expand
Updated
Updated · Stanford Medical Center Report · Jun 29
GLP-1 Drugs Reshape Obesity Care, Cutting Cardiac Events 20% as New Oral Options Expand
3 articles · Updated · Stanford Medical Center Report · Jun 29
Summary
Semaglutide and Tirzepatide have moved beyond diabetes into broad obesity care, with average weight loss of about 15% and 20% respectively and newer uses in heart disease, fatty liver disease and sleep apnea.
Three injectable GLP-1s and 2 FDA-approved pills are now available in the U.S., but clinicians say drug choice still hinges heavily on insurance coverage, side-effect tolerance and whether patients can manage strict dosing rules for oral semaglutide.
Roughly 10% to 15% of patients lose little weight even at maximum dose, while most others hit a slowdown by months 4 to 6 and a plateau by 12 to 18 months as the body adapts.
Gastrointestinal problems remain the main drawback—Stanford clinicians cited nausea, vomiting, constipation and dehydration—and about half of adults stop treatment within a year, with side effects and coverage loss both contributing.
More than 9,000 patients in a 2026 analysis regained nearly 2 pounds a month after stopping semaglutide or tirzepatide, reinforcing clinicians' view that GLP-1s usually function as lifelong treatment and sometimes complement bariatric surgery.
If stopping the medication means weight regain, are patients signing up for a lifetime of injections?
As insurers drop coverage, are GLP-1 drugs creating a new health divide based on wealth?
With drugs that silence 'food noise,' what happens to our cultural and emotional connection to food?
GLP-1 Agonists in Obesity and Cardiovascular Disease: Landmark Outcomes, Mechanisms, and the Challenge of Access for 100 Million Patients
Overview
Obesity and overweight now affect most adults worldwide and are major drivers of cardiovascular disease, both by creating risk factors and through direct biological effects. For years, there were few effective medicines to safely reduce weight and lower heart risk. This changed with the arrival of GLP-1 receptor agonists, which not only help with weight loss but also directly reduce major heart events. Their success marks a new era in cardiometabolic care, offering hope for better management of obesity and heart disease where previous treatments focused mainly on other risk factors.